室性心律失常是導(dǎo)致心臟性猝死的重要原因之一。鈉-葡萄糖共轉(zhuǎn)運蛋白2（SGLT2）抑制劑可以減少室性心律失常的發(fā)生。上市的SGLT2抑制劑有達(dá)格列凈、恩格列凈、卡格列凈和艾托格列凈。SGLT2抑制劑臨床用于治療室性心律失常，其作用機(jī)制為影響離子通道、線粒體和氧化應(yīng)激、心肌纖維化、低血糖和QT間期、能量代謝。總結(jié)了SGLT2抑制劑治療室性心律失常的臨床研究和作用機(jī)制，為開拓室性心律失常的治療提供新思路。

Ventricular arrhythmia is one of the important causes of sudden cardiac death. Sodium-glucose cotransporter 2 (SGLT2) inhibitors can reduce the occurrence of ventricular arrhythmias. The SGLT2 inhibitors available for sale on the market include dapagliflozin, enagliflozin, canagliflozin, and etogliflozin. SGLT2 inhibitors are clinically used to treat ventricular arrhythmias, and their mechanisms of action include affecting ion channels, mitochondria and oxidative stress, myocardial fibrosis, hypoglycemia and QT interval, and energy metabolism. This article summarizes the clinical research and mechanism of action of SGLT2 inhibitors in treatment of ventricular arrhythmias, providing new ideas for exploring the treatment of ventricular arrhythmias.

R972

蘇州市吳江區(qū)“科技興衛(wèi)”項目（WWK202213）